46 related articles for article (PubMed ID: 26739211)
1. Clinical impact of myocardial mTORC1 activation in nonischemic dilated cardiomyopathy.
Yano T; Shimoshige S; Miki T; Tanno M; Mochizuki A; Fujito T; Yuda S; Muranaka A; Ogasawara M; Hashimoto A; Tsuchihashi K; Miura T
J Mol Cell Cardiol; 2016 Feb; 91():6-9. PubMed ID: 26739211
[TBL] [Abstract][Full Text] [Related]
2. The lipid peroxidation product 4-hydroxy-trans-2-nonenal causes protein synthesis in cardiac myocytes via activated mTORC1-p70S6K-RPS6 signaling.
Calamaras TD; Lee C; Lan F; Ido Y; Siwik DA; Colucci WS
Free Radic Biol Med; 2015 May; 82():137-46. PubMed ID: 25617592
[TBL] [Abstract][Full Text] [Related]
3. De novo missense variants in RRAGC lead to a fatal mTORopathy of early childhood.
Reijnders MRF; Seibt A; Brugger M; Lamers IJC; Ott T; Klaas O; Horváth J; Rose AMS; Craghill IM; Brunet T; Graf E; Mayerhanser K; Hellebrekers D; Pauck D; Neuen-Jacob E; Rodenburg RJT; Wieczorek D; Klee D; Mayatepek E; Driessen G; Bindermann R; Averdunk L; Lohmeier K; Sinnema M; Stegmann APA; Roepman R; Poulter JA; Distelmaier F
Genet Med; 2023 Jul; 25(7):100838. PubMed ID: 37057673
[TBL] [Abstract][Full Text] [Related]
4. Loss of eEF1A2 (Eukaryotic Elongation Factor 1 A2) in Murine Myocardium Results in Dilated Cardiomyopathy.
Feng W; Wang L; Veevers J; Liu C; Huang T; Chen J
Circ Heart Fail; 2021 Oct; 14(10):e008665. PubMed ID: 34555936
[No Abstract] [Full Text] [Related]
5. Allelic heterogeneity of TTNtv dilated cardiomyopathy can be modeled in adult zebrafish.
Zhu P; Li J; Yan F; Islam S; Lin X; Xu X
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38412038
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism.
Packer M
Nat Rev Cardiol; 2023 Jul; 20(7):443-462. PubMed ID: 36609604
[TBL] [Abstract][Full Text] [Related]
7. Signaling network model of cardiomyocyte morphological changes in familial cardiomyopathy.
Khalilimeybodi A; Riaz M; Campbell SG; Omens JH; McCulloch AD; Qyang Y; Saucerman JJ
J Mol Cell Cardiol; 2023 Jan; 174():1-14. PubMed ID: 36370475
[TBL] [Abstract][Full Text] [Related]
8. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis.
Packer M
Circulation; 2022 Nov; 146(18):1383-1405. PubMed ID: 36315602
[TBL] [Abstract][Full Text] [Related]
9. Enhanced nuclear localization of phosphorylated MLKL predicts adverse events in patients with dilated cardiomyopathy.
Fujita Y; Yano T; Kanamori H; Nagahara D; Muranaka A; Kouzu H; Mochizuki A; Koyama M; Nagano N; Fujito T; Nishikawa R; Kamiyama N; Tanaka M; Kuno A; Tanno M; Miura T
ESC Heart Fail; 2022 Oct; 9(5):3435-3451. PubMed ID: 35851586
[TBL] [Abstract][Full Text] [Related]
10. Modifications of Titin Contribute to the Progression of Cardiomyopathy and Represent a Therapeutic Target for Treatment of Heart Failure.
Tharp C; Mestroni L; Taylor M
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32859027
[TBL] [Abstract][Full Text] [Related]
11. Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.
Packer M
J Am Heart Assoc; 2020 Aug; 9(16):e016270. PubMed ID: 32791029
[TBL] [Abstract][Full Text] [Related]
12. Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.
Packer M
Eur Heart J; 2020 Oct; 41(39):3856-3861. PubMed ID: 32460327
[TBL] [Abstract][Full Text] [Related]
13. The Giant Protein Titin's Role in Cardiomyopathy: Genetic, Transcriptional, and Post-translational Modifications of TTN and Their Contribution to Cardiac Disease.
Tharp CA; Haywood ME; Sbaizero O; Taylor MRG; Mestroni L
Front Physiol; 2019; 10():1436. PubMed ID: 31849696
[TBL] [Abstract][Full Text] [Related]
14. Covalent targeting of the vacuolar H
Chung CY; Shin HR; Berdan CA; Ford B; Ward CC; Olzmann JA; Zoncu R; Nomura DK
Nat Chem Biol; 2019 Aug; 15(8):776-785. PubMed ID: 31285595
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of Oxytocin in Atherosclerotic Cardiovascular Disease: Mechanisms and Signaling Pathways.
Wang P; Wang SC; Yang H; Lv C; Jia S; Liu X; Wang X; Meng D; Qin D; Zhu H; Wang YF
Front Neurosci; 2019; 13():454. PubMed ID: 31178679
[TBL] [Abstract][Full Text] [Related]
16. Titin mutations and muscle disease.
Kellermayer D; Smith JE; Granzier H
Pflugers Arch; 2019 May; 471(5):673-682. PubMed ID: 30919088
[TBL] [Abstract][Full Text] [Related]
17. New Insights Into the Role of mTOR Signaling in the Cardiovascular System.
Sciarretta S; Forte M; Frati G; Sadoshima J
Circ Res; 2018 Feb; 122(3):489-505. PubMed ID: 29420210
[TBL] [Abstract][Full Text] [Related]
18. Role of titin in cardiomyopathy: from DNA variants to patient stratification.
Ware JS; Cook SA
Nat Rev Cardiol; 2018 Apr; 15(4):241-252. PubMed ID: 29238064
[TBL] [Abstract][Full Text] [Related]
19. Oncometabolic Tracks in the Heart.
Taegtmeyer H; Karlstaedt A; Rees ML; Davogustto G
Circ Res; 2017 Jan; 120(2):267-269. PubMed ID: 28104766
[TBL] [Abstract][Full Text] [Related]
20. Titin-truncating variants affect heart function in disease cohorts and the general population.
Schafer S; de Marvao A; Adami E; Fiedler LR; Ng B; Khin E; Rackham OJ; van Heesch S; Pua CJ; Kui M; Walsh R; Tayal U; Prasad SK; Dawes TJ; Ko NS; Sim D; Chan LL; Chin CW; Mazzarotto F; Barton PJ; Kreuchwig F; de Kleijn DP; Totman T; Biffi C; Tee N; Rueckert D; Schneider V; Faber A; Regitz-Zagrosek V; Seidman JG; Seidman CE; Linke WA; Kovalik JP; O'Regan D; Ware JS; Hubner N; Cook SA
Nat Genet; 2017 Jan; 49(1):46-53. PubMed ID: 27869827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
